Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Vertex’s Trikafta: treating the genetic basis of cystic fibrosis

At the end of 2019, the FDA approved Vertex’s Trikafta, the world’s first triple combination therapy for cystic fibrosis. This drug’s mechanism of action means it treats the underlying genetic cause of the disease in 90% of the CF population. Allie Nawrat investigates the benefit this drug brings to at-need CF patients and how to treat the 10% of patients who remain without effective treatment.

Close
Close
Close

Go Top